Core Requirements for the List: For a substance to be included on the 503B Bulks List, the FDA must determine there is a clinical need
Ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns. Before filing its lawsuit, Novo said, it had sent a formal cease-and-desist request asking Lilly to pull down or meaningfully correct certain ads, but was refused
Our appetite is dialed down, and the rate at which food leaves our stomach slows
Thrive GLP-1, manufactured by Le-Vel as part of their myGLP system, sits somewhere in the middle, a legitimate supplement with real ingredients but effectiveness nowhere near prescription semaglutide or tirzepatide
Insurers declined coverage for obesity treatments, writing them off as cosmetic. As a result, pharmaceutical research into obesity drugs was underfunded, underappreciated, and often doomed
Nauck, M